Clinical Trials Directory

Trials / Completed

CompletedNCT00948155

Measuring Smoking Behaviors While Using Varenicline

Assessment of Smoking Topography and Behaviors During Response to Varenicline

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
48 (actual)
Sponsor
University of Pennsylvania · Academic / Other
Sex
All
Age
21 Years – 65 Years
Healthy volunteers
Accepted

Summary

This study will demonstrate the behavioral responses to varenicline, helping to better understand its mechanisms. Hypotheses for the study are to observe decreases in smoking topography and nicotine cigarette choice on varenicline, relative to placebo; and decreases on day 21 relative to day 7 during varenicline treatment. We also propose to examine if extended duration of treatment has clinical significance in decreasing smoking behaviors, thus increasing the efficacy of varenicline.

Detailed description

This study is designed to examine the behavioral responses a cigarette smoker may have to using varenicline. Behavioral responses may help to better understand its mechanisms which in turn could improve treatment outcomes. The primary hypothesis for the study is to observe decreases in smoking topography, an objective measure of smoking behavior or puffing, on varenicline, relative to placebo; and decreases on day 21 relative to day 7 during varenicline treatment. We will also examine puffing and nicotine cigarette choices during lab visits at baseline, and Days 7 and 21. We also propose to examine if extended duration of treatment has clinical significance in decreasing smoking behaviors, thus potentially increasing the efficacy of varenicline.

Conditions

Interventions

TypeNameDescription
DRUGVareniclineIntervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.

Timeline

Start date
2009-01-01
Primary completion
2010-11-01
Completion
2010-11-01
First posted
2009-07-29
Last updated
2014-12-16
Results posted
2014-12-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00948155. Inclusion in this directory is not an endorsement.